
    
      Enrollment of subjects into this study will occur for up to 4 years. Subjects will receive
      Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require total
      parenteral nutrition or until their conjugated/direct bilirubin has normalized and their
      enteral lipid intake is sufficient to discontinue intravenous lipids.
    
  